Gene upregulated in cancers of the prostate

• US 7,928,212 B2
• Filed: 06/16/2010
• Issued: 04/19/2011
• Est. Priority Date: 10/28/1999
• Status: Expired due to Fees

• Current Assignee: Agensys, Inc. (Astellas Pharma Incorporated)
• Original Assignee: Agensys, Inc. (Astellas Pharma Incorporated)
• Inventors: Raitano, Arthur B., Afar, Daniel E. H., Jakobovits, Aya, Hubert, Rene S., Mitchell, Steve Chappell
• Primary Examiner(s): Yu; Misook
• Assistant Examiner(s): Yao; Lei
• Application Number:
  US12/817,089
• Publication Number:
  US 20100255535A1
• Time in Patent Office: 307 Days
• Field of Search: None
• US Class Current: 536/23.1
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: A61P 37/04 Immunostimulants
• CPC Class Codes: C07K 14/47 from mammals
• CPC Class Codes: C12N 2799/026 where the vector is derived from a baculovirus
• CPC Class Codes: Y02A 50/30 Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

The present invention relates to a novel protein designated 20P2H8 which shares homology with several heterogeneous nuclear ribonucleoproteins (hnRNPs). A full length approximately 3600 bp 20P2H8 cDNA (SEQ ID NO: 1, encoding a 517 amino acid open reading frame (SEQ ID NO: 2), is provided herein.

Claims

1. An isolated nucleotide sequence comprising an uninterrupted sequence of nucleotides that encodes the polypeptide of SEQ ID NO:

2.

2. The isolated nucleotide sequence of claim 1, wherein the sequence comprises the nucleotide sequence of SEQ ID NO:

1.

3. The isolated nucleotide sequence of claim 1, wherein the sequence comprises nucleotides 451 to 2001 of SEQ ID NO:

1.

4. An isolated recombinant expression vector comprising a nucleotide sequence that encodes the amino acid sequence of SEQ ID NO:

2.

5. The recombinant expression vector of claim 4, wherein the nucleotide sequence comprises the nucleotide sequence of SEQ ID NO:

1.

6. The recombinant expression vector of claim 4, wherein the nucleotide sequence comprises nucleotides 451 to 2001 of SEQ ID NO:

1.

7. The recombinant vector of claim 4, wherein the vector further comprises one or more regulatory sequences.

8. The recombinant vector of claim 4, wherein the vector further comprises a stop codon associated with the nucleotide sequence.

9. The recombinant expression vector of claim 4, wherein the vector is a viral vector.

10. The recombinant expression vector of claim 7, wherein the viral vector is a vaccinia, fowlpox, canarypox, adenovirus, influenza, poliovirus, adeno-associated virus, lentivirus, or Sindbis virus.

11. An isolated host cell comprising a recombinant comprising a nucleotide sequence that encodes the amino acid sequence of SEQ ID NO:

2.

12. The host cell of claim 11, wherein the nucleotide sequence comprises the nucleotide sequence of SEQ ID NO:

1.

13. The host cell of claim 11, wherein the nucleotide sequence comprises nucleotides 451 to 2001 of SEQ ID NO:

1.

14. A method of producing a polypeptide, comprising:

providing a host cell, wherein the host cell comprises an expression vector and wherein the expression vector comprises a nucleotide sequence encoding the polypeptide of SEQ ID NO;

2; and

culturing the host cell under conditions to produce the polypeptide.

15. The method of claim 14, wherein the host cell is prokaryotic or eukaryotic.

16. The method of claim 14, wherein the nucleotide sequence encoding the polypeptide comprises the nucleotide sequence of SEQ ID NO:

1.

17. The method of claim 14, further comprising purifying the polypeptide produced.